

# PRODUCT INFORMATION




## Anti-DNP Monoclonal Antibody (Clone 8G11)

Item No. 25863

### Overview and Properties


<b>Contents:</b>	This vial contains 100 µg of protein G-purified monoclonal antibody.
<b>Synonyms:</b>	2,4-Dinitrophenol, 2,4-DNP
<b>Immunogen:</b>	2,4-Dinitrophenol
<b>Form:</b>	Liquid
<b>Storage:</b>	-20°C (as supplied)
<b>Stability:</b>	≥3 years
<b>Storage Buffer:</b>	PBS, pH 7.2, with 50% glycerol and 0.02% sodium azide
<b>Clone:</b>	8G11
<b>Host:</b>	Mouse
<b>Isotype:</b>	IgG1
<b>Applications:</b>	ELISA, immunoprecipitation (IP), and Western blot (WB); the recommended starting dilution for ELISA and WB is 1:1,000 and 5 µg per IP test. Other applications were not tested, therefore optimal working concentration/dilution should be determined empirically.

### Images



Lane 1: Anti-DNP (Clone 8G11) DNP-conjugated HeLa IP (20 µl)  
Lane 2: Anti-DNP (Clone 8G11) Non-conjugated HeLa IP (20 µl)

5 µg of Anti-DNP Monoclonal Antibody (Clone 8G11) was used to immunoprecipitate 50 µg of either DNP-conjugated HeLa or non-conjugated HeLa lysate. mAb-conjugates were captured using 100 µl protein A. mAb-conjugates were removed from protein A with 1X SDS-PAGE loading buffer and run on a reducing 12% acrylamide gel. Conjugates were detected by Western blot using 1 µg/ml Anti-DNP Polyclonal Antibody (Item No. 25864) and appropriate HRP-conjugated secondary antibody.



Lane 1: DNP-conjugated HeLa Lysate (10 µg)  
Lane 2: DNP-conjugated HeLa Lysate (5 µg)  
Lane 3: DNP-conjugated HeLa Lysate (2.5 µg)  
Lane 4: DNP-conjugated HeLa Lysate (1 µg)  
Lane 5: DNP-conjugated HeLa Lysate (0.5 µg)  
Lane 6: Non-conjugated HeLa Lysate (10 µg)  
Lane 7: DNP-conjugated BSA (0.01 µg)  
Lane 8: Non-conjugated BSA (1 µg)

**WARNING**  
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

**SAFETY DATA**  
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

**WARRANTY AND LIMITATION OF REMEDY**  
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/06/2023

**CAYMAN CHEMICAL**  
1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA  
PHONE: [800] 364-9897  
[734] 971-3335  
FAX: [734] 971-3640  
CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM

# PRODUCT INFORMATION



## Description

---

2,4-Dinitrophenol (DNP) is a hapten that induces a strong immune response when attached to proteins or peptides.<sup>1,2</sup> DNP can be incorporated at protein carbonyls *via* covalent linkage of DNP to carbonyl groups using 2,4-dinitrophenylhydrazine (DNPH) or through site-specific incorporation of unnatural amino acids that contain a DNP functional group.<sup>1,3</sup> Immunization with DNP-modified proteins or tumor cells induces antibody formation *in vivo* and has been used in the design of vaccines for clearance of disease-causing cells or viruses and induction of autoimmune diseases such as colitis and thyroiditis in various animal models.<sup>4,5</sup> Cayman's Anti-DNP Monoclonal Antibody can be used for ELISA, Western blot, and immunoprecipitation applications.

## References

---

1. Ren, W., Ji, A., Wang, M.X., *et al.* Expanding the genetic code for a dinitrophenyl hapten. *Chembiochem*. **16(14)**, 2007-2010 (2015).
2. Jasani, B., Thomas, N.D., Navabi, H., *et al.* Dinitrophenyl (DNP) hapten sandwich staining (DHSS) procedure. A 10 year review of its principle reagents and applications. *J. Immunol. Methods* **150(1-2)**, 193-198 (1992).
3. Yang, T., Zhong, P., Qu, L., *et al.* Preparation and identification of anti-2, 4-dinitrophenyl monoclonal antibodies. *J. Immunol. Methods* **313(1-2)**, 20-28 (2006).
4. Berd, D., Maguire, H.C., Jr., Mastrangelo, M.J., *et al.* Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. *Cancer Immunol. Immunother.* **39(3)**, 141-147 (1994).
5. Manne, J., Mastrangelo, M.J., and Berd, D. TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine. *J. Immunol.* **169(6)**, 3407-3412 (2002).

CAYMAN CHEMICAL  
1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA  
PHONE: [800] 364-9897  
[734] 971-3335  
FAX: [734] 971-3640  
CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM